Recent Posts
Connect with:
Sunday / June 16.
HomeminewsKodiak Scraps Eylea Rival

Kodiak Scraps Eylea Rival

Kodiak Sciences has scrapped its attempt at making an anti-VEFG candidate to rival Eylea.

The proposed drug, tarcocimab tedromer, failed two of three Phase III trials. The drug was under development as a treatment for neovascular age-related macular degeneration and diabetic macular oedema.

While results from the studies showed the drug was safe, overall it did not improve vision as effectively as Eylea, Kodiak said.

Kodiak said additional loading doses might have helped achieve better results. But it said, “most critically”, there was an “unforeseen imbalance in cataract adverse events”, the reason for which was “unclear at this time”.